Department of Surgery, University of Utah, Salt Lake City, UT, USA.
Ann Surg Oncol. 2021 Jun;28(6):3157-3168. doi: 10.1245/s10434-020-09267-y. Epub 2020 Nov 3.
Higher socioeconomic status (SES) and non-Hispanic White (NHW) race/ethnicity are associated with higher treatment rates and longer overall survival (OS) among US patients with stage I-II pancreatic ductal adenocarcinoma. The proportion of OS disparities mediated through treatment disparities (PM) and the proportion predicted to be eliminated (PE) if treatment disparities were eliminated are unknown.
We analyzed 2007-2015 data from the Surveillance, Epidemiology, and End Results (SEER) census tract-level database and the National Cancer Database (NCDB) using causal mediation analysis methods to understand the extent to which treatment disparities mediate OS disparities. In the first set of decompositions, race/ethnicity was controlled for as a covariate proximal to SES, and lower SES strata were compared with the highest SES stratum. In the second set, an intersectional perspective was taken and each SES-race/ethnicity combination was compared with highest SES-NHW patients, who had the highest treatment rates and longest OS.
The SEER and NCDB cohorts contained 16,921 patients and 44,638 patients, respectively. When race/ethnicity was controlled for, PMs ranged from 43 to 48% and PEs ranged from 46 to 50% for various lower SES strata. When separately comparing each SES-race/ethnicity combination with the highest SES-NHW patients, results were similar for lower SES-NHW patients but differed markedly for non-Hispanic Black and Hispanic patients, for whom PMs ranged from 60 to 80% and PEs ranged from 55 to 75% for most lower SES strata.
These results suggest that efforts to reduce treatment disparities are worthwhile, particularly for NHB and Hispanic patients, and simultaneously point to the importance of non-treatment-related causal pathways.
在美国患有 I 期- II 期胰腺导管腺癌的患者中,较高的社会经济地位(SES)和非西班牙裔白人(NHW)种族/民族与较高的治疗率和更长的总生存期(OS)相关。通过治疗差异介导的 OS 差异的比例(PM)和如果消除治疗差异预计将消除的比例(PE)尚不清楚。
我们使用因果中介分析方法分析了 2007-2015 年来自监测、流行病学和最终结果(SEER)普查区数据库和国家癌症数据库(NCDB)的数据,以了解治疗差异在多大程度上介导 OS 差异。在第一组分解中,种族/民族被控制为 SES 的近端协变量,并且较低的 SES 阶层与最高 SES 阶层进行了比较。在第二组中,采用交叉观点,将每个 SES-种族/民族组合与最高 SES-NHW 患者进行比较,这些患者的治疗率最高,OS 最长。
SEER 和 NCDB 队列分别包含 16921 名和 44638 名患者。当控制种族/民族时,对于各种较低 SES 阶层,PM 范围从 43%到 48%,PE 范围从 46%到 50%。当分别将每个 SES-种族/民族组合与最高 SES-NHW 患者进行比较时,对于较低 SES-NHW 患者的结果相似,但对于非西班牙裔黑人(NHB)和西班牙裔患者的结果则大不相同,对于这些患者,对于大多数较低 SES 阶层,PM 范围从 60%到 80%,PE 范围从 55%到 75%。
这些结果表明,努力减少治疗差异是值得的,特别是对于 NHB 和西班牙裔患者,同时也指出了非治疗相关因果途径的重要性。